Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | CARM | Common Stock | Award | $0 | +623K | $0.00 | 623K | Jan 24, 2022 | Common Stock | 623K | $0.73 | Direct | F1 |
Id | Content |
---|---|
F1 | 25% of the shares subject to such option shall vest on the first anniversary of the date of grant of the option and an additional 6.25% of the shares underlying the option shall vest at the end of each successive three-month period thereafter until the fourth anniversary of the date of grant of the option. Based on market analysis by Radford of public, pre-commercial and commercial biopharmaceutical companies, the compensation committee of Sesen Bio, Inc ("the Company"), recommended to the Company's board of directors, and the board of directors approved, the grant to the reporting person. |